MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
February 22 2023 - 5:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced today that it will present an oral
presentation describing meal challenge results at the 16th
International Conference on Advanced Technologies & Treatment
for Diabetes (ATTD) in Berlin February 22-25.
Dr. Kevin Kaiserman, Vice President, Medical Affairs, Endocrine
Business Unit for MannKind, will report meal challenge results from
the Afrezza with Basal Combination proof-of-concept study during an
oral presentation delivered on Feb 25.
The data showed that subjects utilizing inhaled Technosphere
Insulin lowered peak glucose levels 30 minutes faster (200 mg/dl at
60 minutes) than subjects utilizing a rapid-acting analogue (RAA)
with an Automated Insulin Delivery (AID) system (264 mg/dl at 90
minutes). Subjects utilizing TI also experienced a significantly
lower mean PPG from 45 to 120 minutes post-meal.
“We believe inhaled insulin is an important option for those
living with type 1 diabetes to reduce their PPG in the first 120
minutes,” said Dr. Kaiserman. “The study revealed a faster and
lower peak in glucose that may assist patients in achieving
improved glycemic control.”
“We are steadfast in our commitment to addressing the serious
unmet need to improve mealtime control for those living with
diabetes,” said Michael Castagna, PharmD, Chief Executive Officer
of MannKind Corporation. “Based on the data collected from this
pilot study we intend to move forward with a larger study this year
to evaluate how we can reduce the diabetes burden as well as
improve a patient’s ability to control their sugars in the first
120 minutes after they eat.”
Twenty-six adults with type 1 diabetes using AID systems
completed the pilot study. The inhaled TI group (21 participants)
utilized an inhaled insulin dose to cover a standardized meal
whereas the AID control group (five participants) used
AID-administered RAA to cover the standardized meal. Each
participant consumed 37g of a nutritional shake (1 can of Boost®).
Glucose was measured by self-monitored blood glucose (SMBG) at
15–30-minute intervals over two hours. The inhaled TI dosing used
in this trial simplified the conversion from RAA that is contained
in the current prescribing information. This dosing regimen was
reported in a recently published study showing this new dose
conversion provides better PPG control and does not give rise to
any new safety concerns such as severe hypoglycemia.
Additional analysis from the ABC trial is expected to be
presented at future conferences.
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking StatementsThis press release
contains forward-looking statements about the implications of
clinical data and plans for future study that involve risks and
uncertainties. Words such as “believes”, “anticipates”, “plans”,
“expects”, “intends”, “will”, “goal”, “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon MannKind’s current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that continued testing of an
investigational drug product may not yield successful results or
results that are consistent with earlier testing, as well as other
risks detailed in MannKind’s filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2021 and subsequent periodic reports on
Form 10-Q and current reports on Form 8-K. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
AFREZZA, TECHNOSPHERE and MANNKIND are registered trademarks of
MannKind Corporation.
For MannKind:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024